Search Results

646 results

  1. CORESTA Congress, Online, 2020, Smoke Science/Product Technology Groups, ST 11

    Extractable and leachable testing of electronic nicotine delivery systems

    MORLEY N.; McGUIGAN S.; THOMAS J.; FEILDEN A.
    Hall Analytical Laboratories Ltd, Manchester, U.K.
    Many electronic nicotine delivery systems (ENDS) contain multiple components which are known to contain substances which have the potential to migrate from the components and potentially be exposed to the user. Thus, the assessment of extractables...
  2. CORESTA Congress, Online, 2020, Smoke Science/Product Technology Groups, ST 14

    In vitro assessment of acute respiratory toxicity

    SHARMA M.(1); STUCKI A.(1); VERSTRAELEN S.(2); FRIJNS E.(2); MAES F.(2); CLIPPINGER A.J.(1)
    (1) PETA International Science Consortium Ltd., Society Building, London, U.K.; (2) VITO, Flemish Institute for Technological Research, Mol, Belgium
    Efficient and effective assessment of inhaled substances using human-relevant approaches is important for product development and risk management. The aim of this project is to assess acute inhalation toxicity of chemicals using an in vitro system,...
  3. CORESTA Congress, Online, 2020, Smoke Science/Product Technology Groups, STPOST 02

    Analysis of highly volatile flavouring compounds in cigarettes smoke

    PINTO M.I.; PORTER R.; GHELLI J.; GOSS C.; THOMPSON N.; DALTON D.; WRIGHT C.
    British American Tobacco, R&D Centre, Southampton, U.K.
    A method for the analysis of highly volatile flavouring compounds in cigarette smoke is proposed. The extraction and concentration of these compounds is challenging because of the complexity of the smoke matrix, and the high vapour pressure and low...
  4. CORESTA Congress, Online, 2020, Smoke Science/Product Technology Groups, STPOST 15

    The comparative analysis of cytokine production by a human 3D airway tissue model following exposure to traditional cigarette smoke, tobacco-heated product and e-cigarette aerosol

    BEDFORD R.(1); ROTHWELL E.(1); MARTIN S.(1); O’HANLON C.(1); McCUNE A.(2); HOLLINGS M.(1)
    (1) Genetic Toxicology, Covance Laboratories Ltd, Harrogate, North Yorkshire, U.K.; (2) Immunology and Immunotoxicology, Covance Laboratories Ltd, Harrogate, North Yorkshire, U.K.
    The battery of regulatory assays currently used to assess the toxicity of aerosol exposure are limited in their ability to identify changes at the cellular and molecular level. This has prompted a shift towards a more holistic systems biology...
  5. CORESTA Meeting, Agronomy/Phytopathology, 2019, Victoria Falls, AP Sustainability Forum

    Agro-Phyto Sustainability Forum

    WILDE L.(1); PRIBIC V.(2); EVANS W.(3); ROYO E.(4); BARGIACCHI E.(5); COLARD S.(6)
    (1) twentyfifty Ltd, Frome, U.K.; (2) JT International S.A., Geneva, Switzerland; (3) Imperial Tobacco Limited, Durban, South Africa; (4) Philip Morris International, Cape Town, South Africa; (5) Consortium INSTM, Firenze, Italy; (6) CORESTA, Paris, France
    In 2015, the United Nations published 17 sustainable development goals and their corresponding targets to be achieved by 2030. Like other sectors, the tobacco and alternative product sectors are likely to impact most of the...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 09

    The ABOUT™ Toolbox: toward the development of consumer-reported outcome measures that matter

    CHREA C.(1); SPIES E.(1); AFOLALU E.(1); BACSO A.(1); CLERC E.(1); MAINY N.(1); BINGGELI P.(1); WEITKUNAT R.(1); ACQUADRO C.(2); SALZBERGER T.(3); CANO S.(4); ABETZ-WEBB L.(5); ROSE J.(6)
    (1) PMI R&D, Philip Morris Products S.A., Neuchatel, Switzerland; (2) Mapi, an ICON plc Company, Lyon, France; (3) University of Economics and Business, Vienna, Austria; (4) ScaleReport, Ltd, Stotfold, U.K.; (5) Patient-Centered Outcomes Assessments, Ltd, Macclesfield Cheshire, U.K.; (6) Rose Research Center, Raleigh, U.S.A.
    Tobacco harm reduction promotes the substitution of reduced-risk products (RRPs) for cigarettes by adult smokers who would otherwise continue to smoke, while preventing RRP initiation among non-users. To operationalize this public health strategy,...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 10

    Development of the ABOUT™–Health & Functioning: results from the preparatory phase

    SPIES E.(1); BACSO A.(1); CHREA C.(1); ABETZ-WEBB L.(2); AFOLALU E.(1); CLERC E.(1); WEITKUNAT R.(1)
    (1) PMI R&D, Philip Morris Products S.A., Neuchatel, Switzerland; (2) Patient-Centered Outcomes Assessments, Ltd, Macclesfield Cheshire, U.K.
    Switching cigarette smokers to significantly less harmful tobacco or nicotine products, or reduced-risk products (RRPs), has been recognized as a valuable and promising approach to reduce smoking-related population harm. Measuring self-reported...
  8. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 11

    Development and validation of the ABOUT™–Dependence measurement instrument to assess perceived dependence on tobacco and nicotine products

    AFOLALU E.(1); CHREA C.(1); SALZBERGER T.(2); ABETZ-WEBB L.(3); CANO S.(4); WEITKUNAT R.(1); ROSE J.(5)
    (1) PMI R&D, Philip Morris Products S.A., Neuchatel, Switzerland; (2) University of Economics and Business, Vienna, Austria; (3) Patient-Centered Outcomes Assessments, Ltd, Macclesfield Cheshire, U.K.; (4) Modus Outcomes, Letchworth Garden City, U.K.; (5) Rose Research Center, Raleigh, U.S.A.
    The development of the ABOUT™–Dependence measurement instrument was initiated to enable assessment of perceived dependence associated with the use of different tobacco and nicotine products (TNPs) and in users of multiple TNPs. We initially developed...
  9. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 12

    Review of current methodologies in evaluating abuse liability of nicotine and tobacco products in the U.S. regulatory environment

    EVANS S.(1); KONG M.C.(2); CAMPBELL L.(2); SHERWOOD N.(3); PRASAD K.(4)
    (1) Turning Point Brands, Louisville, KY, U.S.A.; (2) Altasciences Clinical Research, Laval, Canada; (3) Neil Sherwood Consulting, Nyon, Switzerland; (4) British American Tobacco, R&D, Millbrook, Southampton, U.K.
    Traditional definitions of abuse and misuse do not apply to a consumer product such as tobacco that consumers essentially use ‘as intended’. In contrast to pharmaceutical products, a guidance for abuse liability testing of nicotine and tobacco...
  10. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 29

    Thermochemical and thermophysical mapping of burning superslim and kingsize cigarettes

    EHLERT S.(1,3); CUI H.(2); HEIDE J.(3); XIE F.(2); DENG N.(2); LIU C.(4); McADAM K.(4); WALTE A.(1); ZIMMERMANN R.(3)
    (1) Photonion GmbH, Schwerin, Germany; (2) Zhengzhou Tobacco Research Institute of CNTC, Zhengzhou, Henan, P.R. China; (3) University of Rostock, Dept. of Analytical Chemistry, Rostock, Germany; (4) British American Tobacco, R&D Centre, Southampton, U.K.
    After presenting and publishing the proof of principle of the in-situ thermochemical and thermophysical mapping inside a burning Super Slim (SS) cigarette, we now extended the study scope to other cigarette formats and smoking regimes[1]. A...